View by Specialty

Trending

PC1124Murray_Graphic_01_WEB
November 22, 2024
3 min read
Save

‘Truly alarming’: Life expectancy gap in the US now up to 20 years

Cell Therapy News

SPONSORED CONTENT
Save
SPONSORED CONTENT
July 20, 2020
5 min read
Save

Exploring alternatives to CAR T-cell therapy

Exploring alternatives to CAR T-cell therapy

In this installment of In Practice, Ryan D. Cassaday, MD, explains how to negotiate the delicate balancing act required when discussing alternatives to chimeric antigen receptor T-cell therapy with patients and referring colleagues.

SPONSORED CONTENT
July 15, 2020
3 min read
Save

Discovery of cell surface protein may lead to CAR-T for inflammatory diseases

Discovery of cell surface protein may lead to CAR-T for inflammatory diseases

Cellular senescence has both positive and negative effects in the body.

Trending

PC1124Murray_Graphic_01_WEB
November 22, 2024
3 min read
Save

‘Truly alarming’: Life expectancy gap in the US now up to 20 years

SPONSORED CONTENT
July 15, 2020
1 min read
Save

FDA clears IND application for off-the-shelf, BCMA-directed CAR-T for advanced myeloma

FDA clears IND application for off-the-shelf, BCMA-directed CAR-T for advanced myeloma

The FDA cleared an investigational new drug application for CYAD-211, a chimeric antigen receptor T-cell therapy for the treatment of relapsed or refractory multiple myeloma, according to a press release from the agent’s manufacturer.

SPONSORED CONTENT
July 14, 2020
3 min read
Save

Real-world CAR T-cell therapy as safe, effective as in clinical trial setting

Real-world CAR T-cell therapy as safe, effective as in clinical trial setting

Axicabtagene ciloleucel administered as standard of care appeared as safe and effective as when given during the agent’s pivotal clinical trial, according to study results published in Journal of Clinical Oncology.

SPONSORED CONTENT
July 11, 2020
1 min read
Save

Nine investigators to share $6.75 million for blood cancer research

Three organizations awarded grants totaling $6.75 million to fund research into blood cancers.

SPONSORED CONTENT
July 09, 2020
2 min read
Save

FDA clears IND application for stem cell-derived CAR-T targeting CD19-positive tumors

FDA clears IND application for stem cell-derived CAR-T targeting CD19-positive tumors

The FDA cleared an investigational new drug application for FT819, a chimeric antigen receptor T-cell therapy for the treatment of CD19-positive tumors, according to a press release from the agent’s manufacturer.

SPONSORED CONTENT
July 09, 2020
1 min read
Save

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL

In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

SPONSORED CONTENT
July 08, 2020
1 min read
Save

Retreatment with CAR-T therapy shows clinical efficacy in lymphoma

Retreatment with CAR-T therapy shows clinical efficacy in lymphoma

In a small sample, retreatment of patients with large B-cell lymphoma showed good response, notably in patients who had complete response on initial treatment, according to a poster presented at ASCO 2020 Virtual Scientific Program.

SPONSORED CONTENT
July 08, 2020
1 min read
Save

FDA places clinical hold on trial for off-the-shelf CAR-T for advanced myeloma

FDA places clinical hold on trial for off-the-shelf CAR-T for advanced myeloma

The FDA placed a clinical hold on a phase 1 study designed to evaluate UCARTCS1A for the treatment of patients with relapsed or refractory multiple myeloma, according to a press release from the agent’s manufacturer.

SPONSORED CONTENT
July 06, 2020
2 min read
Save

Dual target CAR T-cell therapy effective, durable, less toxic in lymphoma

A novel CAR T-cell therapy targeting both CD19 and CD22 showed less toxicities than current CAR T-cell therapies while producing complete response with accepted regimens, according to a study presented at ASCO2020 Virtual Scientific Program.

View more